Holen Sie sich die Stockscreener-App
41.35
1.97%
-0.83
Handel nachbörslich:
41.00
-0.35
-0.85%
Schlusskurs vom Vortag:
$42.18
Offen:
$42.02
24-Stunden-Volumen:
1.15M
Relative Volume:
0.91
Marktkapitalisierung:
$4.93B
Einnahmen:
$10.60M
Nettoeinkommen (Verlust:
$-252.45M
KGV:
-13.34
EPS:
-3.1
Netto-Cashflow:
$-158.91M
1W Leistung:
-12.25%
1M Leistung:
-18.04%
6M Leistung:
+40.17%
1J Leistung:
+549.14%
1-Tages-Spanne:
$39.50
$42.32
1-Wochen-Bereich:
$39.50
$56.00
52-Wochen-Spanne:
$5.68
$56.00
Avidity Biosciences Inc Stock (RNA) Company Profile
Firmenname
Avidity Biosciences Inc
Sektor
Branche
Telefon
858-401-7900
Adresse
10578 SCIENCE CENTER DRIVE, SAN DIEGO, CA
Vergleichen Sie RNA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| RNA | 41.35 | 4.93B | 10.60M | -252.45M | -158.91M | -3.10 |
| VRTX | 467.01 | 119.87B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 762.00 | 83.27B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 567.90 | 33.96B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 232.27 | 30.18B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.87 | 24.42B | 3.30B | -501.07M | 1.03B | 11.54 |
Avidity Biosciences Inc Stock (RNA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-09-24 | Eingeleitet | Goldman | Buy |
| 2024-08-28 | Eingeleitet | Barclays | Overweight |
| 2024-05-03 | Eingeleitet | BofA Securities | Buy |
| 2024-03-14 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-05-22 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2023-03-31 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2022-07-20 | Eingeleitet | Chardan Capital Markets | Buy |
| 2022-07-12 | Eingeleitet | Raymond James | Strong Buy |
| 2021-09-07 | Eingeleitet | Evercore ISI | Outperform |
| 2021-06-17 | Eingeleitet | Needham | Buy |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Outperform |
| 2020-07-07 | Eingeleitet | Cowen | Outperform |
| 2020-07-07 | Eingeleitet | Credit Suisse | Outperform |
| 2020-07-07 | Eingeleitet | SVB Leerink | Outperform |
| 2020-07-07 | Eingeleitet | Wells Fargo | Overweight |
Alle ansehen
Avidity Biosciences Inc Aktie (RNA) Neueste Nachrichten
FY2024 EPS Estimates for RNA Decreased by Cantor Fitzgerald - MarketBeat
Los Angeles Capital Management LLC Takes Position in Avidity Biosciences, Inc. (NASDAQ:RNA) - MarketBeat
State of New Jersey Common Pension Fund D Buys Shares of 44,898 Avidity Biosciences, Inc. (NASDAQ:RNA) - MarketBeat
Assetmark Inc. Invests $566,000 in Avidity Biosciences, Inc. (NASDAQ:RNA) - MarketBeat
Avidity Biosciences (NASDAQ:RNA) Shares Down 7.8%Time to Sell? - MarketBeat
RA Capital Management's Strategic Acquisition in Avidity Bioscie - GuruFocus.com
Avoro Capital Advisors LLC Increases Stake in Avidity Biosciences Inc - GuruFocus.com
Avidity Biosciences unveils new cardiology development candidates - BioWorld Online
RNA Stock Hits Record High on Entering the Cardiac Disease Space - Yahoo Finance
US Bancorp DE Cuts Stock Position in Avidity Biosciences, Inc. (NASDAQ:RNA) - MarketBeat
Avidity Bio Has Surged 416% This Year — And That's Before Today's 'Game-Changing' News - Yahoo! Voices
Avidity Biosciences stock soars to all-time high of $50.86 By Investing.com - Investing.com Canada
Avidity Biosciences stock soars to all-time high of $50.86 - Investing.com
Avidity Biosciences jumps 16%; reaches all-time high (RNA:NASDAQ) - Seeking Alpha
Avidity Biosciences (NASDAQ:RNA) Hits New 52-Week HighShould You Buy? - MarketBeat
Avidity Biosciences (NASDAQ:RNA) Receives "Buy" Rating from Needham & Company LLC - MarketBeat
Assessing Avidity Biosciences: Insights From 10 Financial Analysts - Benzinga
Avidity Biosciences, Inc. (NASDAQ:RNA) Receives Average Rating of "Buy" from Analysts - MarketBeat
Avidity Biosciences to Host Investor and Analyst Event Focused on Precision Cardiology Candidates and First Look at Next-Generation Technology Innovations on November 12, 2024 - PR Newswire
Avidity Biosciences Reports Second Quarter 2023 Financial Results and Recent Highlights - GuruFocus.com
Avidity Biosciences (RNA) Stock Surges On Positive AOC 1020 Trial Results - Barchart
Avidity Biosciences' SWOT analysis: RNA stock poised for growth in precision cardiology - Investing.com
Avidity Biosciences Unveils Advances in Cardiology Research - TipRanks
Avidity Biosciences, Inc. Announces AOC 1072 and AOC 1086 as Initial Precision Cardiology Development Candidates and Shared First Look At Its Next-Generation Technology Innovations - Marketscreener.com
Avidity Biosciences Announces New Precision Cardiology Development Candidates to Treat Rare Genetic Cardiomyopathies and Provides First Look at Next-Generation Technology Innovations - Quantisnow
Selling US$1.0m Of Avidity Biosciences Stock Rewarded Insiders - Simply Wall St
Avidity Biosciences Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Canada Finance
431,210 Shares in Avidity Biosciences, Inc. (NASDAQ:RNA) Bought by Fiera Capital Corp - MarketBeat
Avidity Biosciences CFO sells $4.8 million in stock - Investing.com India
Avidity Biosciences CFO sells $4.8 million in stock By Investing.com - Investing.com Canada
Wellington Management Group LLP's Strategic Acquisition in Avidi - GuruFocus.com
Avidity Biosciences Reports Third Quarter 2024 Financial Results and Recent Highlights - BioSpace
Avidity Biosciences Reports Strong Q3 Progress and Outlook - TipRanks
Avidity Biosciences, Inc. (RNA) Reports Q3 Loss, Lags Revenue Estimates - MSN
Avidity Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Avidity Bio's DMD Drug Shows 25% Dystrophin Boost; Reports $1.6B Cash Position | RNA Stock News - StockTitan
Analysts Estimate Avidity Biosciences, Inc. (RNA) to Report a Decline in Earnings: What to Look Out for - Yahoo Finance
Avidity Biosciences (NASDAQ:RNA) Trading Up 6.5%What's Next? - MarketBeat
Vanguard Group Inc's Strategic Acquisition in Avidity Biosciences Inc - GuruFocus.com
Avidity Biosciences to Host Investor and Analyst Event Focused o - GuruFocus.com
Avidity Biosciences to Host Investor and Analyst Event Focused on Precision Cardiology Candidates and First Look at Next-Generation Technology Innovations on November 12, 2024 – Company AnnouncementFT.com - Financial Times
Avidity Biosciences' (RNA) "Buy" Rating Reaffirmed at Needham & Company LLC - MarketBeat
Avidity Biosciences advances FSHD therapy trial By Investing.com - Investing.com Canada
Avidity Biosciences target held at $59 by Goldman Sachs - Investing.com Canada
Chardan Capital Raises Avidity Biosciences (NASDAQ:RNA) Price Target to $65.00 - MarketBeat
Avidity Biosciences Pursues Potential Accelerated Approval Path with Initiation of Biomarker Cohort in FORTITUDE™ Trial for Delpacibart Braxlosiran (del-brax/AOC 1020) in People Living with Faciosca - StreetInsider.com
Avidity Biosciences advances FSHD therapy trial - Investing.com
Avidity Biosciences Pursues Potential Accelerated Approval Path with Initiation of Biomarker Cohort in FORTITUDE™ Trial for Delpacibart Braxlosiran (del-brax/AOC 1020) in People Living with Facioscapulohumeral Muscular Dystrophy - StockTitan
Avidity Biosciences Announces Inducement Grants Under Nasdaq Lis - GuruFocus.com
Avidity Biosciences, Inc. (NASDAQ:RNA) Shares Purchased by China Universal Asset Management Co. Ltd. - MarketBeat
Cartography Announces Appointment of Troy Wilson, Ph.D., J.D., to its Board of Directors - StockTitan
Finanzdaten der Avidity Biosciences Inc-Aktie (RNA)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.66%
1.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):